82950-04-7

Basic information

• Product Name: aBrUra
• CAS NO: 82950-04-7
• Molecular Weight: 323.1
• Mol File: 82950-04-7.mol

Chemical Properties

• CAS DataBase Reference: aBrUra(CAS DataBase Reference)
• NIST Chemistry Reference: aBrUra(82950-04-7)
• EPA Substance Registry System: aBrUra(82950-04-7)

Safety Data

• Hazardous Substances Data: 82950-04-7(Hazardous Substances Data)

Upstream product

• 957-75-5 5-bromouridine 
• 35837-20-8 2',3'-anhydro-1-β-D-arabinofuranosyl-5-bromo-uracil 
• 3083-77-0 araU 

Downstream Products

• 17245-47-5 (3aS)-3c-hydroxy-2t-hydroxymethyl-(3ar,9ac)-2,3,3a,9a-tetrahydro-furo[2',3':4,5]oxazolo[3,2-c]pyrimidine-6,8-dione 

Relevant articles and documents

Synthesis, cytotoxic effect and antiviral activity of 1-(β-D- arabinofuranosyl)-5-bromo-N4-substituted cytosine and 1-(β-D- arabinofuranosyl)-5-bromo-4-methoxypyrimidin-2(1H)-one derivatives

A convenient and mild synthesis of 5-bromo-N4-substituted-1-(β-D- arabinofuranosyl)cytosine and 5-bromo-O4-methyl-1-(β-D- arabinofuranosyl)pyrimidin-2(1H)-one derivatives by selective oxyfunctionalization of the corresponding 4-thionucleosides with 3,3- dimethyldioxirane is reported. The cytotoxicity and the antiviral activity against parainfluenza 1 (Sendai virus) of all new synthesized products are also reported.

Bromination at C-5 of pyrimidine and C-8 of purine nucleosides with 1,3-dibromo-5,5-dimethylhydantoin

Treatment of the protected and unprotected nucleosides with 1,3-dibromo-5,5-dimethylhydantoin in aprotic solvents such as CH 2Cl2, CH3CN, or DMF effected smooth bromination of uridine and cytidine derivatives at C-5 of pyrimidine rings as well as adenosine and guanosine derivatives at C-8 of purine rings. Addition of Lewis acids such as trimethylsilyl trifluoromethanesulfonate enhanced the efficiency of bromination.

Anti-HCV nucleoside derivatives

The present invention comprises novel and known purine and pyrimidine nucleoside derivatives which have been discovered to be active against hepatitis C virus (HCV). The use of these derivatives for the treatment of HCV infection is claimed as are the novel nucleoside derivatives disclosed herein.

A mild and efficient methodology for the synthesis of 5-halogeno uracil nucleosides that occurs via a 5-halogeno-6-azido-5,6-dihydro intermediate

A mild and efficient methodology for the synthesis of 5-halogeno (iodo, bromo, or chloro) uracil nucleosides has been developed. 5-Halo-2'-deoxyuridines 4a-c (84-95%), 5-halouridines 7a-c (45-95%), and 5-haloarabinouridines 8a-c (65-95%) were synthesized in good to excellent yields by the reaction of 2'-deoxyuridine (2), uridine (5) and arabinouridine (6), respectively with iodine monochloride, or N-bromo (or chloro)succinimide, and sodium azide at 25-45°C. These C-5 halogenation reactions proceed via a 5-halo-6-azido-5,6-dihydro intermediate (3), from which HN3 is eliminated, to yield the 5-halogeno uracil nucleoside. The 5-halo-6-azido-5,6-dihydro intermediate products (10a, 10b) could be isolated from the reaction of 3',5'-di-O-acetyl-2'-deoxyuridine (9) with iodine monochloride or N-bromosuccinimide and sodium azide at 0°C. The isolation of 10a, 10b indicates that the C-5 halogenation reaction proceeds via a 5-halo-6-azido-5,6-dihydro intermediate.